Vivos Therapeutics (Vivos Therapeutics) EBIT : $-16.08 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics EBIT?

Vivos Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-3.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-16.08 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vivos Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -135.32%. Vivos Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -324.44%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vivos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -277.63%.

Vivos Therapeutics EBIT Historical Data

The historical data trend for Vivos Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics EBIT Chart

Vivos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-10.62

-11.96

-20.27

-25.03

-17.30

Vivos Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-5.01	-4.52	-3.49	-4.28	-3.79

Competitive Comparison of Vivos Therapeutics's EBIT

For the Medical Devices subindustry, Vivos Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivos Therapeutics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vivos Therapeutics's EV-to-EBIT falls into.

Vivos Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.08 Mil.

Vivos Therapeutics (NAS:VVOS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vivos Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-15.14 * ( 1 - 0% )	/	( (11.079	+	11.298)	/ 2 )
=	-15.14	/	11.1885
=	-135.32 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.73	-	4.479	-	( 1.643	-	max(0, 7.289	-	2.461	+	1.643	))
=	11.079

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.804	-	4.965	-	( 2.611	-	max(0, 8.07	-	3.611	+	2.611	))
=	11.298

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Vivos Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-15.14	/	( ( (4.699 + max(-5.997, 0))	+	(4.634 + max(-6.587, 0)) )	/	2 )
=	-15.14	/	( ( 4.699	+	4.634 )	/	2 )
=	-15.14	/	4.6665
=	-324.44 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.202	+	0	+	0.616)	-	(4.479	+	2.138	+	0.198)
=	-5.997

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.525	+	0	+	0.475)	-	(4.965	+	2.398	+	0.224)
=	-6.587

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vivos Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-16.075	/	5.790
	=	-277.63 %

Vivos Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Therapeutics (Vivos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120

Website

https://www.vivos.com

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.

Executives

Ronald Kirk Huntsman	director, 10 percent owner, officer: Chairman & CEO	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman	officer: Chief Financial Officer	6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow	director	REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson	director	2 MUSICK, IRVINE CA 92618
Anja B Krammer	director	C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh	director, 10 percent owner, officer: Chief Medical Officer	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129